Dr David Kisor, Glenn Sawyer


Recent Developments in PGx: Predictive Biomarker Identification & Relevance

calender-icon Thursday, May 26, 2022 | 11:00 am – 12:00 pm PT | 2:00 pm – 3:00 pm ET

Program Sponsored by Agena Bioscience®

Newly identified biomarkers, and evidence to support their potential pharmacogenomic  relevance, can help address challenges involved with optimizing personalized drug therapy.

In this webinar, Dr. David Kisor from Manchester University will present the latest evidence supporting newly identified (predictive) biomarkers for pharmacogenomics as well as evaluating the relevance of certain existing biomarkers. He will introduce a new resource that will be available for comparing and contrasting Clinical Pharmacogenetic Implementation Consortium and U.S. Food and Drug Administration PGx data.


In addition, Dr. Kisor will provide an overview of his updated educational modules that discuss the study of genetic variations in terms of an individual’s response to drugs.

Following Dr. Kisor’s presentation, Glenn Sawyer from Agena Bioscience will provide a brief, high-level overview of the company’s PGx capabilities.


Agena Bioscience logo

Add This Event to Your Calendar

Webinar Register Now

Presented By:

Dr David Kisor

Dr. David Kisor

Dr. David Kisor as a Professor of Pharmaceutical Sciences and Pharmacogenomics and the Director of Pharmacogenomics at Manchester University, in Fort Wayne, IN. He is responsible for directing pharmacogenomics across programs in the College of Pharmacy, Natural and Health Sciences. Dr. Kisor received his PharmD from The Ohio State University, completed a postdoctoral fellowship in therapeutic drug monitoring and pharmacokinetics at Ohio State, and has integrated pharmacogenetics and pharmacogenomics with pharmacokinetic subject matter since 1998. Dr. Kisor is very engaged in pharmacogenomics education, having been involved with the American Association of Colleges of Pharmacy Pharmacogenomics Special Interest Group (AACP PGx SIG) in defining/refining competency statements in genetics/genomics for pharmacists as well as leading the effort to provide the first certification program in PGx in the United States.
Glenn Sawyer

Glenn Sawyer

Glenn Sawyer is Associate Director of Clinical Genetics at Agena Bioscience, which encompasses pharmacogenetics, hereditary genetics and infectious disease. With over 20 years in the biotechnology industry Glenn has experience as a R&D scientist, sales, training and marketing with an emphasis on instrumentation and molecular diagnostic applications.